louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05408364: Probiotics Effects to Initial Periodontal Treatment
Official title: Clinical and Microbiological Evaluation of Probiotics as an Adjunct to Initial Periodontal Treatment in Chronic Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Periodontitis
Keywords: bifidobacterium
chronic periodontitis
dental scaling
probiotic
root planing
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2022-06-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the clinical and microbiological effects of Bifidobacterium animalis subsp. lactis DN-173010 containing yoghurt as an adjunct to mechanical periodontal treatment.

Detailed description: The aim of this study is to evaluate the clinical and microbiological effects of Bifidobacterium animalis subsp. lactis DN-173010 containing yoghurt as an adjunct to mechanical periodontal treatment.

Thirty chronic periodontitis patients were randomized into 2 groups. As adjunctive to MPT, Group 1 consumed 2×108 CFU/day of Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt while Group 2 natural yoghurt once daily for 28 days. Subgingival plaque samples were obtained from 2 periodontal sites with probing pocket depth (PPD) of 4≤PPD\<7 mm via paper-points at baseline, 28th day, 3rd month. Samples were cultured to evaluate total viable count (TVC), the proportions of obligate anaerobes (OA) and Bifidobacterium species (B) (TVC%). The full-mouth recorded clinical parameters were plaque index, gingival index, PPD, bleeding on probing, and clinical attachment level.

Eligibility criteria: Inclusion Criteria:

* chronic periodontitis patients with radiographically detected horizontal bone loss
* the presence of at least 2 teeth with one approximal site with a probing pocket depth (PPD) of 4≤SD\<7 mm (5-7 mm) and a GI of ≥2 mm in each quadrant,
* previously untreated periodontitis, systemically healthy

Exclusion Criteria:

* Systemic diseases
* Antibiotics and anti-inflammatory drugs within 3 months before the study
* Untreated caries lesions or local retention factors
* Allergic reactions to lactose or fermented milk products
* Previous probiotic supplements in diet
* Smoking
* Pregnancy

Primary outcomes:
measure: Probing Depth
timeFrame: 28 days
Secondary outcomes:
measure: Gingival Index
timeFrame: 28 days
measure: Plaque Index
timeFrame: 28 days
measure: Bleeding on probing
timeFrame: 28 days
measure: Clinical attachment level
timeFrame: 28 days
measure: microbiological parameters
timeFrame: 28 days
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Marmara University
state: Maltepe
Study officials:
affiliation: Marmara University, Faculty of Dentistry, Department of Periodontology
name: Bahar Kuru, Prof. Dr.
role: STUDY_DIRECTOR
affiliation: Marmara University, Faculty of Dentistry, Department of Periodontology
name: Hafize Öztürk Özener, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06751264: Evaluation of the Efficacy and Safety of Microwave Ablation of Uterine Adenomyosis Under Improved Ultrasound Guidance
Official title: Evaluation of the Efficacy and Safety of Microwave Ablation of Uterine Adenomyosis Under Improved Ultrasound Guidance
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Adenomyosis of Uterus
Lead sponsor: Peking University Aerospace Center Hospital
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 137
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the safety and efficacy of segmental power adjustment combined with uterine cavity hydro-isolation in microwave ablation of adenomyosis


Eligibility criteria: Inclusion Criteria:

1. UFs or AM diagnosed by pathology and ultrasound；
2. Relevant symptoms such asabnormal uterine bleeding, secondary anemia, progressive dysmenorrhea and enlargement of the uterus；
3. Voluntarily undergo MWA；
4. a confirmed available safe transabdominal puncture path；

Exclusion Criteria:

1. Pregnancy or malignancy；
2. Severe and uncorrectable coagulation disorders；
3. Severe cardiac, liver, and renal dysfunction；
4. Anesthesia allergy.

Primary outcomes:
measure: The rates of endometrial injury
timeFrame: From enrollment to the end of treatment at 3 months
Secondary outcomes:
measure: The reduction rate of adenomyosis volume
timeFrame: From enrollment to the end of treatment at 1 year
measure: complication
timeFrame: From enrollment to the end of treatment at 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01137864: Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards
Official title: Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards: a Multicenter Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients Under Antimicrobial Therapy
Keywords: Emergency wards
Hospitalization
Adults
Antimicrobial therapy
Lead sponsor: Henri Mondor University Hospital
Sponsor class: OTHER
First posted: 2010-06-07
Enrollment: 255
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: CONTEXT: Antibiotics are frequently used in hospital but the appropriateness of prescriptions ranged between 25-50%. The intervention of infectious disease specialists (IDS) could improve the appropriateness of prescriptions and reduce their use. The impact of IDS has not been yet fully estimated using a randomized trial to compare the quality of care of patients who will benefit of the intervention.

OBJECTIVES: To show using a randomized trial that patients hospitalized in emergency wards with IDS advice will receive more appropriate antimicrobial therapy but less exposure to antibiotics, as compared to patients who will not receive IDS advice.

METHODS: Prospective randomized trial comparing antibiotic exposure and appropriateness of prescriptions in two groups of patients admitted in emergency wards:

Control group: antibiotic prescriptions will be initiated and managed by the attending physicians Intervention group: antibiotic prescriptions will be systematically evaluated by the IDS and changed if judged necessary by the attending physicians, following IDS' advice.

STUDY PROCESS: The study will took place in the emergency wards of 4 university hospitals. For each ward, the period of the study will be 2 x 4 weeks.Total duration of the study: 12 months.


Eligibility criteria: Inclusion Criteria:

* Adults Hospitalized in emergency wards Receiving antimicrobial therapy for active infection or prolonged surgical prophylaxis Therapy prescribed by the attending ward physician

Exclusion Criteria:

* Patients receiving antimicrobial therapy not prescribed by the attending ward physician

Primary outcomes:
measure: Appropriateness of antimicrobial therapy
timeFrame: Between days 1 and 3
Secondary outcomes:
measure: Clinical impact
timeFrame: Between days 1 and 3
measure: Antibiotic exposure
timeFrame: 14 days
Other outcomes:
Locations:
city: Créteil
country: France
facility: Henri Mondor University Hospital
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Philippe Lesprit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02114164: Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies
Official title: A Comparative Study of CO2 Exchange Patterns Between Valve-free Trocar (AirSeal®) Versus Standard Trocar (Endopath®) During Robotic Prostatectomies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Pneumoperitoneum
Keywords: AirSeal
Trocar
Carbon Dioxide Exchange and Absorption
Lead sponsor: OhioHealth
Sponsor class: OTHER
Collaborators: name: SurgiQuest, Inc.
First posted: 2014-04-15
Enrollment: 109
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.

Detailed description: The primary observation to be made is the level of carbon dioxide in the arterial blood, specifically when the patient is insufflated and deflated during the surgery. As a result of the consistent pressure that the AirSeal® system maintains, carbon dioxide will be absorbed in lower levels when compared to the standard of care systems in which fluctuations in intra-peritoneum pressure are seen.

Eligibility criteria: Inclusion Criteria:

* Age\>18
* Eligible and elect to undergo robotic prostatectomy surgery @ OhioHealth Dublin Methodist Hospital

Exclusion Criteria:

* Age \< 18
* Emergency surgery
* Ascites
* BMI\>44 or \<18

Primary outcomes:
measure: Intraoperative Pneumoperitoneal Pressure (mmHg)
timeFrame: Through end of procedure, an average of 156 minutes
Secondary outcomes:
measure: Intraoperative Arterial Blood Gas Carbon Dioxide (mmHg).
timeFrame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
measure: End-tidal Carbon Dioxide Pressure (mmHg)
timeFrame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
measure: Carbon Dioxide Elimination (mmHg)
timeFrame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
measure: Intraoperative Arterial Blood Gas Oxygen (mmHg).
timeFrame: Baseline, 60 minutes, and end of procedure, an average of 156 minutes
measure: Number of Ventilator Interventions
timeFrame: Through end of procedure, an average of 156 minutes
measure: Procedure Time (Minutes)
timeFrame: Through end of procedure, an average of 156 minutes
measure: Smoke Evacuation Quality
timeFrame: Through end of procedure, an average of 156 minutes
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Dublin Methodist Hospital
state: Ohio
Study officials:
affiliation: OhioHealth
name: Ronney Abaza, MD,FACS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Abaza R, Martinez O, Murphy C. Randomized Controlled Comparison of Valveless Trocar (AirSeal) vs Standard Insufflator with Ultralow Pneuomoperitoneum During Robotic Prostatectomy. J Endourol. 2021 Jul;35(7):1020-1024. doi: 10.1089/end.2020.1025. Epub 2021 Jan 21.
Clinical trial NCT03081364: Patient Registry Of Magnetic Resonance Imaging in Non-Approved DEvices
Official title: Patient Registry Of Magnetic Resonance Imaging in Non-Approved DEvices
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Magnetic Field Exposure
Keywords: Cardiac Implanted Device
Lead sponsor: Saint Luke's Health System
Sponsor class: OTHER
First posted: 2017-03-16
Enrollment: 532
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: For all patients in whom a clinical MRI examination is felt to be important in the patients care, and in whom the potential benefits clearly outweigh the risks of an MRI exam as referred from various primary and/or subspecialty physicians.

Brief summary: The investigators are providing MRI in patients with non-MRI approved CIED's (Cardiac Implanted Electronic Devices)

Detailed description: At Saint Luke's Hospital, despite growing evidence to the contrary, there is extremely limited data and experience with performing MRIs on patient with abandoned and epicardial leads in patients with non-approved ICDs and PMs. There is a limited mechanism to discuss this issue with the patient, screen the patient and assess their device beforehand, monitor them during the MRI examination, keep track of pulse sequences used, assess their devices after (and if necessary, resume prior programming before any changes), and to maintain that experience. The objective of this study is to create a protocol for an MRI at the commonly used magnetic strength of 1.5 T in patients that do not have conditional pacemakers and/or defibrillators and have abandoned or epicardial leads and maintain a registry of participants, devices involved, MRI examinations and pulse sequences used, and to keep records of any follow up events.

Eligibility criteria: Inclusion Criteria:

* Anyone with a cardiac device

Exclusion Criteria:

* Anyone who cannot consent for themselves or who don't have a durable power of attorney

Primary outcomes:
measure: Change in Device Function
timeFrame: 3 years
measure: Change in Thresholds of Pacing Lead
timeFrame: 3 years
measure: Dysrhythmias Noted During Scan
timeFrame: 3 years
measure: Oxygen Saturation
timeFrame: 3 years
measure: Change in heart rate
timeFrame: 3 years
measure: Patient Comments
timeFrame: 3 years
measure: Interference Between the Implanted Cardiac Electronic Device and MRI
timeFrame: 3 years
measure: Change in blood pressure
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: St. Luke's Hospital, Kansas City, Missouri
name: Sanjaya K Gupta, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gupta SK, Ya'qoub L, Wimmer AP, Fisher S, Saeed IM. Safety and Clinical Impact of MRI in Patients with Non-MRI-conditional Cardiac Devices. Radiol Cardiothorac Imaging. 2020 Oct 22;2(5):e200086. doi: 10.1148/ryct.2020200086. eCollection 2020 Oct.
Clinical trial NCT06833164: ERAP1,2 in Recalcitrant Warts
Official title: Serum ERAP1 and ERAP2 Levels in Patients With Recalcitrant Warts
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Warts
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2025-02-18
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Two hundred individuals were separated into two groups. Group (I) patients with resistant warts (n=100), and group (II) age- and sex-matched subjects with history of treated warts with no recurrence (n=100). They were recruited from the Dermatology Outpatient Clinic at Benha University Hospitals

Brief summary: The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.


Eligibility criteria: Inclusion Criteria:

• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

Exclusion Criteria:

* Patients with genital warts
* Patients on systemic steroids or other immunosuppressive treatments
* Immunocompromised individuals
* Patients suffering from chronic systemic diseases
* Pregnant women

Primary outcomes:
measure: SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2
timeFrame: ONE YEAR
Secondary outcomes:
Other outcomes:
Locations:
city: Benha
country: Egypt
facility: faculty of medicine Benha University
state: Qalubia
Study officials:
affiliation: Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University
name: Ihab Y. Abdallah, MD
role: STUDY_CHAIR
affiliation: Professor of Microbiology and Immunology, Faculty of Medicine, Benha University
name: Nehad A.Fouad, MD
role: STUDY_DIRECTOR
affiliation: Benha University
name: Ola S Ebrahim, MBBCh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02505464: Pregnancies Complicated by Fetal Anomalies
Official title: Characteristics of Pregnancies Complicated by Fetal Anomalies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pregnancy
Congenital Abnormalities
Lead sponsor: University of Tennessee
Sponsor class: OTHER
Collaborators: name: Regional One Health
First posted: 2015-07-22
Enrollment: 500
Sex: ALL
Minimum age (years): 1
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients referred to, or being seen in the Ob-Gyn High Risk Clinics (ROH-MFM Clinic, ROH-CHRP, ROH-Rout Center, Le Bonheur Fetal Center) will be potential participants.

Brief summary: The focus of this research is to create a repository of ultrasonographic images and their corresponding medical data from pregnant women (the mothers of the fetuses that are imaged), focusing on fetal anomalies. These women will visit the obstetrical clinics at Regional One Health and the Le Bonheur Fetal Center.

Detailed description: 1. Repository data will be collected from the medical record and entered into the data base after the patient has completed the appointment.
2. Data collection will continue into the postpartum period for each participant.
3. Data collection will continue for the child during the treatment of the medical condition, up to approximately 6 months of age if required by the condition.

Eligibility criteria: Inclusion Criteria:

* Pregnant females

  * age 8 years to 50 years
  * who have referred to the clinic for high risks pregnancies
* Infants (male and female) born with anomalies

Exclusion Criteria:

* Non-pregnant females.

Primary outcomes:
measure: Data Collection
timeFrame: From the initial visit @ the High Risk Clinic through the infants approx. age of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: LeBonheur Children's Hospital
state: Tennessee
city: Memphis
country: United States
facility: Methodist LeBonheur Healthcare, LeBonheur Fetal Center
state: Tennessee
city: Memphis
country: United States
facility: Regional One Health, OB/GYN Clinic, Maternal Fetal Medicine
state: Tennessee
city: Memphis
country: United States
facility: Regional One Health, Regional Medical Center, Rout Center for Women and Children
state: Tennessee
city: Memphis
country: United States
facility: Regional One Health Center for High Risk Pregnancies
state: Tennessee
Study officials:
affiliation: Vice-Chair and Professor, MFM Fellowship Director Obstetrics and Gynecology
name: Norman Meyer, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05063864: Post-Hysterectomy Nursing Support Program
Official title: Determining the Effectiveness of the Post-Hysterectomy Nursing Support Program: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hysterectomy
Keywords: hysterectomy
nursing support program,
menopausal symptoms
sexuality
depression
quality of life
Lead sponsor: Suleyman Demirel University
Sponsor class: OTHER
First posted: 2021-10-01
Enrollment: 60
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Objective: This study was conducted to evaluate the effectiveness of the nursing support program developed for women undergoing hysterectomy.

Background: Hysterectomy is an important surgical intervention that affects women physically, sexually and psychosocially.

Method: The study is a single blind, randomized controlled study conducted at the Department of Obstetrics and Gynecology in a university hospital between November 2017 and November 2018. 60 women who had hysterectomy were divided into experimental and control groups and It was evaluated on the 1-2 day, 6-7 day and 2nd month. In the study, the nursing support program was applied only to women in the experimental group.

Detailed description: Aim: This study was conducted to evaluate the effectiveness of the nursing support program developed for women who had hysterectomy.

Methods: A prospective, randomised controlled study was conducted in the gynaecology clinic of a university hospital between November 2017 and November 2018. It was conducted in a single-blind, randomised controlled trial with a total of 60 women in the experimental and control groups. A nursing support program had been developed for women who have had a hysterectomy. The program developed for the experimental group and the routine program for routine maintenance and control group were applied. The initial evaluation was carried out postoperative on the 1st-2nd day, the second assessment was carried out on the 6th-7th day and the third evaluation was carried out at 2 months. The first interview was carried out in the hospital, and the second and third interviews were carried out with home visits. The sociodemographic data form, postoperative evaluation form, Female Sexual Function Index (FSFI), Epidemiological Studies and Central Depression Scale (EAMDS), Menopausal Symptoms Evaluation Scale (MSDS) and SF-12 quality of life scale were used to collect data.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis benign hysterectomy and bilateral oophorectomy
* Having no communication problems.

Exclusion Criteria:

* Clinical diagnosis vaginal hysterectomy
* Clinical diagnosis psychiatric disorders and therefore used drugs

Primary outcomes:
measure: Nursing Support Program
timeFrame: postoperative on the 2 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Isparta
country: Turkey
facility: Suleyman Demirel University
Study officials:
affiliation: Suleyman Demirel University
name: Kübra Yilmaz
role: PRINCIPAL_INVESTIGATOR
References: